Navigation Links
Ortho Biotech Announces NDA Submission for Trabectedin for the Treatment of Relapsed Ovarian Cancer
Date:11/20/2008

BRIDGEWATER, N.J., Nov. 20 /PRNewswire/ -- Ortho Biotech Products, L.P. today announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL(R) (doxorubicin HCI liposome injection)for the treatment of women with relapsed ovarian cancer (ROC). If approved, trabectedin combined with DOXIL will provide a new, non-platinum treatment option for these patients in the United States.

The application follows the completion of a multicenter, randomized Phase III study, ET743-OVA-301, one of the largest studies conducted in ROC, comparing the combination of trabectedin and DOXIL to DOXIL alone in 672 patients. The study showed that patients treated with the combination treatment had a statistically significant improvement in the primary endpoint of progression-free survival (PFS, or the length of time during and after treatment in which the disease does not progress) compared to patients treated with DOXIL alone.

"This is a significant milestone in the development of trabectedin, an agent with a novel mechanism of action that holds promise for patients with relapsed ovarian cancer," said Craig Tendler, M.D., Vice President, Medical Affairs, Oncology/ Nephrology, Ortho Biotech Products, L.P. "We are confident in the strength of the data supporting the application and look forward to working with the FDA throughout the regulatory review process."

Relapsed ovarian cancer refers to epithelial carcinoma of the ovary that recurs after treatment. According to the National Cancer Institute (NCI), it is estimated that 21,650 women will be diagnosed with, and 15,520 women will die from ovarian cancer in the U.S. in 2008.

Trabectedin is being developed under a license from PharmaMar, and DOXIL is marketed by Ortho Biotech Products, L.P. in the U.S.

About t
'/>"/>

SOURCE Ortho Biotech Products, L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. New Orthopedic Oncology Fellowship Program at Mount Clemens Brings Highly Trained Surgeons to State
2. Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit
3. Dental Implants Effective for Orthodontic Treatment
4. Hanger Orthopedic Group, Inc. Receives Favorable New Code for WalkAide
5. Zimmer Holdings to Collaborate with the American Orthopaedic Association for Funding Post-Graduate Medical Education
6. Dr. Ron Greenspan has Been Selected for the 2008 Best of San Diego Award in the Orthodontists Category by the U.S. Local Business Association
7. Orthodontists Offer Sweet Incentives for Tricky Halloween Treats
8. Hanger Orthopedic Group, Inc. Exceeds Estimates on a 10% Sales Increase and a 28% EPS Increase to $0.23 for the Third Quarter 2008
9. Archus Orthopedics Performs First Facet Replacement Procedure With an Artificial Disc
10. Hanger Orthopedic Group, Inc. Announces Underwritten Public Offering by Shareholder
11. Amy Street, Certified Prosthetist and Orthotist, Joins BridgePoint Medical Partner, Charlotte Orthotic and Prosthetic Center (COPC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... (PRWEB) September 18, 2014 According to the ... from eczema, with many of them being children. In fact, ... diagnosed as babies and children. The millions of children who ... be brought on by eczema. A new book has been ... they are and to find relief from the condition over ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 SpineFrontier ... team and surgeon partners in Less Exposure Surgery ... SpineFrontier, Tamara authored an extensive education curriculum and ... Masters in Science in Organizational Leadership, and has ... for eleven years. Bringing her to the team ...
(Date:9/18/2014)... 18, 2014 First Choice Emergency ... rooms in the United States, named Douglas J. Harrison, ... City-Lakes facility. , “We are pleased to welcome ... director of our new Missouri City-Lakes facility,” said Dr. ... Emergency Room. , Dr. Harrison received his undergraduate ...
(Date:9/18/2014)... N-Zyme Scientifics LLC achieved a major developmental milestone ... mere 8 months after company startup. Its novel product ... enzyme used in the “Biologics” industry for discovery and ... pathology on Mass Spec devices. PRIME™ is being sold ... market (PNGase F PRIMETM). N-Zyme is currently evaluating ...
(Date:9/17/2014)... September 18, 2014 Recently, BambooIndustry.com, an outstanding ... of bamboo floorings . There are more than 1000 ... has launched a big promotion for these useful items. Each ... 30 % off. , “We are very proud to ... to say, all these items are made with natural materials ...
Breaking Medicine News(10 mins):Health News:New Book Helps Millions of Children Deal With The Emotional Pains of Suffering From Eczema 2Health News:SpineFrontier Inc. Makes Bold Move to Expand Its Internal Training Team to Collaborate With The LESSociety’s Less Exposure Surgery® University To Educate Surgeons. 2Health News:First Choice Emergency Room Announces Dr. Douglas J. Harrison as Medical Director of Missouri City - Lakes, Texas Facility 2Health News:N-Zyme Scientifics Announces Successful Product Launch 2Health News:More Than 1000 Items Added To BambooIndustry.com’s Bamboo Flooring Collection 2
... a newly developed drug, which is aimed at a particular ... tumour growth, is active in patients with advanced cancers and, ... The drug, ACE-041, targets a different molecular pathway to ... treat cancer. Results from a phase I clinical ...
... surgery should receive a risk assessment before their procedure ... in the legs or lungs, according to research at ... that 1 in 9 patients at highest risk based ... clot-preventing medications after surgery. Published in the November ...
... into mice with metastatic melanoma has resulted in permanent ... cancer, according to an article to be published in ... Clinical Investigation . The online version is now available. ... modified lentivirus to introduce a potent anti-melanoma T cell ...
... federal agencies recently cosponsored a set of expert work ... to psychological adjustment and traumatic brain injury (TBI). ... behavioral neuroscience at Boston University School of Medicine, chaired ... Dr. Kaloupek,s work at the National Center for PTSD ...
... of six national participants in a pilot study that ... families have a smoother care experience and better outcomes ... to reliably adhere to best practice standards. The ... the Society of Thoracic Surgeons (STS) will study clinician ...
... have been stymied for years over the fact that people ... response to the pathogen antibodies that turn out to ... Medical Center can explain why: Some of the earliest and ... the virus until after it,s already invaded a healthy cell. ...
Cached Medicine News:Health News:Researchers find new target for stopping tumors developing their own blood supply 2Health News:Researchers find new target for stopping tumors developing their own blood supply 3Health News:Assessment tool predicts blood clot risk after plastic surgery 2Health News:Assessment tool predicts blood clot risk after plastic surgery 3Health News:Gene therapy for metastatic melanoma in mice produces complete remission 2Health News:Researchers identify PTSD measures for use in traumatic brain injury research 2Health News:Lung cancer patients are the centerpiece for Northwestern medicine quality of care study 2Health News:Why so many antibodies fail to protect against HIV infection 2
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 /PRNewswire/ ... Summary GlobalData,s new ... provides key market data on the BRIC Gynecological ... of US dollars, volume (in units) and average ... Female Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) and ...
(Date:9/17/2014)... YORK , Sept. 17, 2014 /PRNewswire/ ... growth during the last decade due to ... natural calamities and technological advancements. This BCC ... within various segments of the ambulance and ... transportation equipment, blood and hemorrhage control devices, ...
(Date:9/17/2014)... YORK , Sept. 17, 2014 Pomerantz ... PDL BioPharma, Inc. ("PDL BioPharma" or the "Company") (NASDAQ: ... S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ... BioPharma and certain of its officers and/or directors have ... Act of 1934.  On September 17, ...
Breaking Medicine Technology:BRIC Gynecological Devices Market Outlook to 2020 2BRIC Gynecological Devices Market Outlook to 2020 3Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PDL BioPharma, Inc. - PDLI 2
... studies affirmed the clinical benefits of,ACTEMRA -, ... Phase III studies,showed that patients who suffer from ... achieved significant improvements in signs and,symptoms when treated ... compared with methotrexate alone. The final results of,both ...
... PTC124 Highlighted in Multiple Presentations at North ... N.J. and ORLANDO, Fla., Oct. 24 ... from a randomized,Phase 2a European study demonstrated ... statistically significant improvements,in the chloride channel function ...
Cached Medicine Technology:ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 2ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 3ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 4ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 5ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 6PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients 2PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients 3PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients 4PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients 5PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients 6
... When it comes to ventral hernia repair, ... While a hernia is often best treated with ... concern about the risk of bowel adhesions to ... mesh, an innovative product designed to meet the ...
... dual-sided ePTFE mesh designed for ventral hernia repair. ... to minimize visceral attachment to the prosthesis. On ... to promote tissue growth. This ingrowth side has ... is nearly equivalent to polypropylene mesh. Bard Dulex ...
... Since its introduction in 1958, Bard mesh ... other products are compared. Bard mesh was ... first developed the "tension-free" hernia repair many ... "a safe and ideal" substance for permanent ...
... Modified Kugel patch repair is a minimally ... through a small 4-6 cm incision and ... repair performed through an open, anterior approach ... regional anesthesia.,The Modified Kugel patch is a ...
Medicine Products: